Equibles does not estimate personal net worth.
Get an email with a short summary when MiNK Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get INKT alertsThe proxy statement of MiNK Therapeutics, Inc. reports total compensation of $402,479 for Marc Van Dijk in fiscal 2024, including a base salary of $341,796. Disclosed compensation is on record for 4 fiscal years. Marc Van Dijk has spoken on 1 earnings call across 1 company, most recently for MiNK Therapeutics, Inc. on August 13, 2024. MiNK Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at MiNK Therapeutics, Inc. includes Melissa Orilall (CFO), Austin Charette (Chief Accounting Officer), Dr. John Holcomb (Board Member) and 5 others.
“We are rapidly advancing MiNK-215 and IL-15 armored FAP-targeting CAR invariant natural killer T cell therapy, that's a mouthful, but it's targeting tumor stroma.”
Source not stated
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | MiNK Therapeutics, Inc. (INKT) | Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | $341,796 | $402,479 |
| 2023 | MiNK Therapeutics, Inc. (INKT) | Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | $333,989 | $568,829 |
| 2022 | MiNK Therapeutics, Inc. (INKT) | Chief Scientific Officer | $252,334 | $651,174 |
| 2021 | MiNK Therapeutics, Inc. (INKT) | Chief Scientific Officer | — | $107,074 |
